Ken Griffin Cidara Therapeutics, Inc. Transaction History

Citadel Advisors LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$0.64 - $0.92 $54,103 - $77,773	84,536 New	84,536 $77,000
Q4 2022 Feb 14, 2023	BUY	$0.48 - $13.08 $144,773 - $3.95 Million	301,612 New	301,612 $229,000
Q2 2022 Aug 15, 2022	SELL	$0.43 - $0.91 $29,599 - $62,639	-68,835 Reduced 54.55%	57,350 $28,000
Q4 2021 Feb 14, 2022	BUY	$1.18 - $2.18 $118,641 - $219,185	100,544 Added 392.12%	126,185 $160,000
Q3 2021 Nov 15, 2021	BUY	$1.48 - $2.35 $18,908 - $30,023	12,776 Added 99.31%	25,641 $57,000
Q2 2021 Aug 16, 2021	SELL	$1.87 - $2.7 $15,840 - $22,871	-8,471 Reduced 39.7%	12,865 $25,000
Q1 2021 May 17, 2021	BUY	$2.06 - $3.01 $43,952 - $64,221	21,336 New	21,336 $57,000
Q2 2020 Aug 14, 2020	SELL	$2.39 - $4.0 $24,934 - $41,732	-10,433 Closed	0 $0
Q1 2020 May 15, 2020	SELL	$1.74 - $4.26 $15,595 - $38,182	-8,963 Reduced 46.21%	10,433 $26,000
Q4 2019 Feb 14, 2020	BUY	$1.77 - $3.84 $8,434 - $18,297	4,765 Added 32.57%	19,396 $74,000
Q1 2018 May 11, 2018	BUY	$4.0 - $8.15 $58,524 - $119,242	14,631 New	14,631 $59,000

Ticker CDTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,075,696
Market Cap $1.43B
Description
Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifu...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.